{"id":19127,"date":"2021-03-12T14:25:28","date_gmt":"2021-03-12T12:25:28","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=19127"},"modified":"2021-03-12T14:25:28","modified_gmt":"2021-03-12T12:25:28","slug":"astrazeneca-pristate-i-lietuva-dar-144-tukst-covid-19-vakcinos-doziu","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/2021\/03\/12\/astrazeneca-pristate-i-lietuva-dar-144-tukst-covid-19-vakcinos-doziu\/","title":{"rendered":"\u201eAstraZeneca\u201c pristat\u0117 \u012f Lietuv\u0105 dar 14,4 t\u016bkst. COVID-19 vakcinos dozi\u0173"},"content":{"rendered":"<p><strong>Penktadien\u012f \u012f Lietuv\u0105 atgabenta \u0161e\u0161toji farmacijos kompanijos \u201eAstraZeneca\u201c vakcin\u0173 nuo koronaviruso (COVID-19) siunta. J\u0105 sudaro 14,4 t\u016bkst. dozi\u0173, kurios \u0161iandien bus paskirstytos savivaldyb\u0117ms.<\/strong><\/p>\n<p>I\u0161 viso Lietuv\u0105 jau pasiek\u0117 115,7 t\u016bkst. \u201eAstraZeneca\u201c vakcinos dozi\u0173, o vien \u0161i\u0105 savait\u0119 j\u0173 pristatyta 48 t\u016bkst. Iki kovo 12 d. gyventoj\u0173 skiepijimui sunaudota 62,1 t\u016bkst. \u0161io gamintojo vakcinos dozi\u0173.<\/p>\n<p>Kovo 12 d. duomenimis, Lietuvoje nuo COVID-19 paskiepyta kiek daugiau nei 240 t\u016bkst. gyventoj\u0173, arba 8,6 proc. visuomen\u0117s.<\/p>\n<p>\u0160alyje vykstant vyresnio am\u017eiaus \u017emoni\u0173 vakcinacijai, pagal am\u017eiaus grupes jau paskiepyta gyventoj\u0173:<\/p>\n<p>\u2022\u00a060-69 met\u0173 \u2013 10,4 proc.;<br \/>\n\u2022\u00a070-79 met\u0173 \u2013 26,3 proc.;<br \/>\n\u2022\u00a080 met\u0173 ir vyresni\u0173 \u2013 34,3 proc.<\/p>\n<p>I\u0161samesn\u0117 vakcinacijos statistika yra pateikiama <a href=\"https:\/\/experience.arcgis.com\/experience\/cab84dcfe0464c2a8050a78f817924ca\/page\/page_3\/\" target=\"_blank\" rel=\"noopener\">Statistikos departamento \u0161vieslent\u0117je<\/a>.<\/p>\n<p>\u012e Lietuv\u0105 atvykus naujoms vakcin\u0173 siuntoms, informacija apie jas yra atnaujinama <a href=\"https:\/\/sam.lrv.lt\/lt\/naujienos\/sam-informuoja-apie-covid-19-vakcinos-pristatymus-i-lietuva-nuolat-atnaujinama\" target=\"_blank\" rel=\"noopener\">Sveikatos apsaugos ministerijos interneto svetain\u0117je<\/a>.<\/p>\n<p>Gyventoj\u0173 vakcinacijos plan\u0105 ir kit\u0105 aktuali\u0105 informacij\u0105 apie vakcinas rasite interneto svetain\u0117je <a href=\"https:\/\/koronastop.lrv.lt\/lt\/vakcinavimas\">Koronastop.lt<\/a>.<\/p>\n<p><em>SAM Spaudos tarnyba<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Penktadien\u012f \u012f Lietuv\u0105 atgabenta \u0161e\u0161toji farmacijos kompanijos \u201eAstraZeneca\u201c vakcin\u0173 nuo koronaviruso (COVID-19) siunta. J\u0105 sudaro 14,4 t\u016bkst. dozi\u0173, kurios \u0161iandien bus paskirstytos savivaldyb\u0117ms. I\u0161 viso Lietuv\u0105 jau pasiek\u0117 115,7 t\u016bkst. \u201eAstraZeneca\u201c vakcinos dozi\u0173, o vien \u0161i\u0105 savait\u0119 j\u0173 pristatyta 48 t\u016bkst. Iki kovo 12 d. gyventoj\u0173 skiepijimui sunaudota 62,1 t\u016bkst. \u0161io gamintojo vakcinos dozi\u0173. Kovo&hellip;<\/p>\n","protected":false},"author":3,"featured_media":19128,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[100],"tags":[],"class_list":["post-19127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-del-covid-19","category-100","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-4Yv","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2021\/03\/18817_eee058ca5fe776121767cf3cede061aa.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/19127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/comments?post=19127"}],"version-history":[{"count":2,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/19127\/revisions"}],"predecessor-version":[{"id":19130,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/posts\/19127\/revisions\/19130"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/media\/19128"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/media?parent=19127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/categories?post=19127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/lt_lt\/wp-json\/wp\/v2\/tags?post=19127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}